Power Law company profile

Structure Therapeutics

Biotech & Life Sciences · South San Francisco, United States · Founded 2016 · IPO 2023 Unicorn

Specializes in the discovery and development of drugs against a type of targets called GPCR

Valuation

$1.51B

Market cap · May/2026

Featured in Unicorn$1B+ valuation tier · Power Law dataset 2026

Investors

12 investors on Structure Therapeutics's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 2 investors entered at this stage

Qiming Venture Partners

Eight Roads Ventures

Series B+ 10 investors entered at this stage

Citadel

Woodline Partners

Sequoia

Deep Track Capital

Sage Partners

Stork Capital

Piper Heartland Healthcare Capital

Terra Magnum Capital Partners

Janus Henderson Investors

Monashee Capital Corp.

Global footprint

Where Structure Therapeutics has talent and traffic

AI talent share

1.0% of workforce is AI talent
(2 of 202 staff)

Core AI10.5%

Other AI10.5%

Non-AI workforce20099.01%

Workforce by country

🇺🇸 United States · South San Francisco HQ

Book a demo for the full country breakdown

Web traffic by country

24K monthly visits
across markets

🇺🇸 United States53.8%

🏳️ Korea22.9%

🏳️ Republic of9.6%

🇫🇷 France9.2%

🇬🇧 United Kingdom3.3%

Top 5 markets shown

Market sentiment

What the market is saying about Structure Therapeutics

An AI-synthesized read of the highest-engagement posts about Structure Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Structure Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles